SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Decline in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 67,700 shares, a decline of 42.8% from the January 31st total of 118,400 shares. Based on an average trading volume of 127,400 shares, the short-interest ratio is presently 0.5 days. Currently, 0.9% of the company’s shares are short sold.

Analysts Set New Price Targets

SABS has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.40.

Institutional Investors Weigh In On SAB Biotherapeutics

Several large investors have recently added to or reduced their stakes in SABS. Northern Trust Corp purchased a new position in shares of SAB Biotherapeutics during the fourth quarter worth approximately $43,000. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics in the third quarter worth approximately $52,000. Diadema Partners LP purchased a new position in SAB Biotherapeutics during the 4th quarter worth $114,000. Geode Capital Management LLC raised its position in SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares in the last quarter. Finally, HB Wealth Management LLC lifted its holdings in shares of SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after buying an additional 128,800 shares during the period. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Stock Performance

Shares of SABS traded down $0.15 during trading hours on Monday, reaching $1.56. 31,799 shares of the company traded hands, compared to its average volume of 152,387. The stock’s fifty day moving average price is $2.87 and its 200 day moving average price is $3.00. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 12-month low of $1.53 and a 12-month high of $6.30.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.